SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS

The treatment of choice in advanced ovarian cancer is a cytoreductive surgery combined with chemotherapeutic treatment. This complex and aggressive surgery is associated with high postoperative complication rates that may result in a strong negative impact on the clinical results due to the delay with the start of adjuvant chemotherapy as well as the costs from the surgical process. Multimodal prehabilitation has emerged as an innovative intervention that focuses on optimizing physiological and psychological resilience to withstand the upcoming stress of surgery. It has been shown to reduce postoperative complications in major abdominal surgery, but has not been assessed yet in abdominal onco-gynecological surgery.

NCT Number	NCT04862325
Lead Sponsor	Hospital Clinic of Barcelona
Conditions	Advanced Ovarian Cancer
Enrollment	158 participants
Start Date	2021-04-20
Primary Completion	2026-04-28 (estimated)
Study Completion	2026-04-28 (estimated)
Updated on ClinicalTrials.gov	2026-08-06